FORE Biotherapeutics Announces Oral Presentation of Phase 1/2a Plixorafenib Data at the Society for Neuro-Oncology 2023 Annual Meeting

Contributed by: Business Wire

Tags

Biotechnology
Health
Pharmaceutical
Clinical Trials
Oncology
Plixorafenib

More Like This

FORE Biotherapeutics Announces Oral Presentation at SNO 2023 Reporting Updated Phase 1/2a Results for Plixorafenib in BRAF V600 Advanced Solid Tumors, Including Novel Data for Patients with BRAF V600 Primary CNS Tumors

FORE Biotherapeutics to Present Plixorafenib Nonclinical Data Highlighting Potential Differentiation at the 2023 AACR-NCI-EORTC International Conference

PR Newswire associated0

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)

Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Business Wire logo

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting

New Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO Meeting

Business Wire logo

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week